Table 1.
Tumorigenicity of BHK-21 transfectants expressing mutant E1A oncoproteins differing in their abilities to form p300 complexes and induce cytolytic susceptibility
| Cell line | Recipient | Tumor
incidence*
|
TPD50† | ||||
|---|---|---|---|---|---|---|---|
| No. of cells
innoculated
| |||||||
| 103 | 104 | 105 | 106 | 107 | |||
| BHK-neo | Hamster | 1/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3.2 |
| BHK-D5 | Hamster | — | — | — | — | 0/3 | ≥7.5 |
| BHK-NCd13.3 | Hamster | — | — | 0/3 | 0/3 | 1/9 | ≥7.4 |
| BHK-NCd13.3 | Nude mouse | 0/3 | 0/3 | 3/3 | 3/3 | 3/3 | 4.5 |
| BHK-PSd18.2T | Hamster | 1/6 | 0/6 | 3/6 | 5/6 | 4/5 | 5.2 |
| BHK-PSd18.2T | Nude mouse | 0/3 | 0/3 | 3/3 | 3/3 | 2/2 | 4.5 |
BHK-D5 cells consistently form tumors in nude mice (5). The tumor that developed in a hamster challenged with BHK-NCd13.3 cells was E1A-negative and likely represents a contaminant of the clone. Differences in tumor producing efficiency of less than one log (e.g., BHK-PSd18.2T—hamster vs. nude mouse) are not significant.
*
Tumor incidence, number of animals with progressive tumors per number of challenged animals.
†
TPD50, logarithm of the cell number required to cause tumors in 50% of animals (30).